Royalty Pharma plc
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $7.10B | $10.14B | $1.79B |
| Jun 2022 | $7.11B | $10.41B | $2.11B |
| Sep 2022 | $6.11B | $10.42B | $991.6M |
| Dec 2022 | $6.12B | $9.53B | $1.71B |
| Mar 2023 | $6.12B | $9.82B | $1.98B |
| Jun 2023 | $6.13B | $9.81B | $2.17B |
| Sep 2023 | $6.13B | $9.59B | $936.4M |
| Dec 2023 | $6.14B | $10.08B | $477.0M |
| Mar 2024 | $6.14B | $9.86B | $843.0M |
| Jun 2024 | $7.60B | $9.75B | $1.76B |
| Sep 2024 | $6.61B | $10.26B | $950.1M |
| Dec 2024 | $6.61B | $10.34B | $929.0M |
| Mar 2025 | $6.62B | $9.78B | $1.09B |
| Jun 2025 | $7.00B | $9.49B | $631.9M |
| Sep 2025 | $8.57B | $9.62B | $938.9M |
| Dec 2025 | $8.57B | $9.71B | $618.7M |
| Mar 2026 | $8.58B | $9.94B | $586.4M |
| Jun 2026 | $8.58B | $9.79B | $812.0M |